Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Moriggl Richard,

Beiträge für wissenschaftliche Veranstaltungen

Vortrag

Dey, S; Sorger, H; Vieyra-Garcia, PA; de Araujo, ED; Graf, R; Spiegl, B; Lazzeri, I; Herling, M; Neubauer, HA; Merkel, O; Heitzer, E; Gunning, PT; Kenner, L; Moriggl, R; Wolf, P (2021): Chromosome # 17q (17q11.2-17q21.31) gain is a disease marker and therapeutic vulnerability in Sezary Syndrome. 4th Inflammatory Skin Disease Summit, New York, NY, United States, NOV 03-06, 2021. Exp Dermatol (30), S2 14-14.

Neubauer, HA; Suske, T; Schonefeldt, S; Tangermann, S; Boersma, A; Rulicke, T; Bekiaris, V; Kenner, L; Moriggl, R (2020): The gain-of-function STAT5B(N642H) mutation as a driver of mature T cell leukemia/lymphoma. AACR Annual Meeting, Philadelphia, PA, United States, JUN 22-24, 2020. Cancer Res (80), 16 2752.

Orlova, A; Kosack, L; Popa, AM; Viczenczova, C; Lercher, A; de Araujo, ED; Gunning, P; Moriggl, R; Bergthaler, A (2020): Restoration of tumor immunosurveillance in tasmanian devil facial tumor disease. AACR Annual Meeting, Philadelphia, PA, United States, JUN 22-24, 2020. Cancer Res (80), 16 5636.

Park, JS; Tin, G; de Araujo, ED; Orlova, A; Sorger, H; Grebien, F; Heyes, E; Geletu, M; Villalonga, R; Sampedro, A; Sedighi, A; Herling, M; Mustjoki, S; Eram, MS; Ahmar, S [and 7 others] (2020): A potent and selective small molecule degrader of STAT5 for the treatment of hematological malignancies. AACR Annual Meeting, Philadelphia, PA, United States, JUN 22-24, 2020. Cancer Res (80), 16 LB-108.

Neubauer, HA; Suske, T; Pham, HTT; Zahma, S; Tangermann, S; Prchal-Murphy, M; Maurer, B; Sexl, V; Valent, P; Boersma, A; Rülicke, T; Bekiaris, V; Kenner, L; Moriggl, R (2019): The gain of function STAT5B N642H mutation as a driver of mature T-Cell leukemia/lymphoma. Cytokines 2019: 7th Annual Meeting of the International Cytokine & Interferon Society; OCT 20-23, 2019; Vienna, Austria. 2019.

Neubauer, H; Pham, HTT; Suske, T; Spirk, K; Zahma, S; Tangermann, S; Prchal-Murphy, M; Maurer, B; Sexl, V; Valent, P; Boersma, A; Rülicke, T; Kenner, L; Moriggl, R (2018): The role of the gain-of-function STAT5BN642H mutation in the development of leukemia/lymphoma in different hematopoietic lineages. From Receptors and Kinases towards Transcriptional Regulators: Cancer Genome Landscapes and their Therapeutic Targets; MAY 6-9, 2018; Seggau, Stmk, Austria. 2018.

Greiner, G; Witzeneder, N; Berger, A; Schmetterer, K; Eisenworth, G; Schiefer, A; Roos, S; Popow-kraupp, T; Müllauer, L; Zuber, J; Sexl, V; Kenner, L; Sperr, WR; Mayerhofer, M; Valent, P; Hoermann, G (2017): ccl-2 Is A Kit D816v-dependent Modulator Of The Bone Marrow Microenvironment In Systemic Mastocytosis: Cod: T210. Euromedlab 2017 Athen, Athen, Greece, June 11-15, 2017. Clinical Chemistry and Laboratory Medicine (55) 709-709.

Gruber, ES; Birner, P; Merkel, O; Bergmann, M; Schoppmann, SF; Park, J; Moriggl, R; Tse, W; Kenner, L (2017): The coactivator oncogene AF1Q associates with STAT3 activation downstream of MET action in gastro-esophageal cancer patients. AACR, Washington DC, United States, April 1-5, 2017. Cancer Research (70), 13 4463-4463.

Prutsch, N; Sanda, T; Wu, L; Turner, S; Jaeger, U; Staber, P; Steinberger, P; Moriggl, R; Mueller, M; Kenner, L; Merkel, O (2017): The TYK2-STAT1 pathway in aggressive T-Cell Lymphoma: A new therapeutic intervention site? ÖGBMT, Innsbruck, Austria, Sep 25-27, 2017. Oncology Research And Treatment (40) 239-239.

Gleixner, KV; Schneeweiss, MA; Herrmann, H; Blatt, K; Berger, D; Eisenwort, G; Greiner, G; Byrgazov, K; Hoermann, G; Konopleva, M; Waliul, I; Gunning, PT; Maeda, H; Moriggl, R; Deininger, MW [and 3 others] (2016): Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml. 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego, CA, United States, DEC 03-06, 2016. Blood (128), 22

Maurer, B; Nivarthi, H; Prchal-Murphy, M; Wingelhofer, B; Chen, D; Winkler, S; Schlederer, M; Pham, HTT; Kenner, L; Sexl, V; Kolbe, T; Kralovics, R; Muller, M; Rülicke, T; Moriggl, R (2016): Activated Stat5 Drives Peripheral T Cell Lymphomas. 21st Congress of the European-Hematology-Association, Copenhagen, DENMARK, Denmark, JUN 09-12, 2016. Haematologica (101), S1 567-567.

Prutsch, N; Sanda, T; Turner, S; Wu, L; Müller, M; Jäger, U; Staber, P; Simonitsch-Klupp, I; Alvarez-Hernandez, A; Gurnhofer, E; Suske, T; Grebien, F; Stoiber, D; Schlederer, M; Moriggl, R [and 2 others] (2016): The TYK2-STAT1 pathway in aggressive T-Cell Lymphoma: A novel therapeutic intervention site? -Jahrestagung Österreichische Gesellschaft für Hämatologie und Onkologie (OeGHO); März 17-19, 2016; Vienna, Austria.

Prutsch, N; Sanda, T; Wu, L; Turner, S; Jaeger, U; Staber, P; Steinberger, P; Moriggl, R; Mueller, M; Kenner, L; Merkel, O (2016): The TYK2-STAT1 pathway in aggressive T-Cell Lymphoma: A new therapeutic intervention site. Jahrestagung der ­Deutschen, Österreichischen und ­Schweizerischen ­Gesellschaften für Hämatologie und ­Medizinische Onkologie, Leipzig, Germany, Germany, OCT 14–18, 2016. Oncol Res Treat (39), S3 239-239.

Moriggl, M; Javaheri, T (2015): Ewing sarcoma mouse development manifests in juveniles and requires Apoptosis escape and cell cycle progression. -Ewing Meeting; JUN 14-17, 2015; Paris, FRANCE.

Moriggl, R (2015): Illuminating STAT5 Biology in Cancers Through Gain or Loss of Function. -International Conference on Cytokine Signaling in Cancer; MAI 23-29, 2015; Kreta, Greece.

Moriggl, R (2015): GH-induced Jak2-Stat5 signalling and the influence by the glucocorticoid receptor pathway in liver cancer or metabolic diseases. -FASEB Meeting, Steamboat Springs, "The Growth Hormone/Prolactin Family in Biology and Disease"; JUL 11-19, 2015; Colarado, USA.

Moriggl, R (2015): Aberrant STAT5 gene dosage and hyperactivation status by cytokine or mutated tyrosine kinase signalling drives disease. -EMBO 8th Young Investigator Meeting in Warsaw; JUN 24-26, 2015; Warsaw, USA.

Morrigl, R (2015): Translational JAK-Stat phenotypes with implications for solid or hematopoietic cancer development. -LBI Annual Meeting – “From Translational Models to Targeted Therapy”; NOV 8-11, 2015; Vienna, Austria.

Pencik, J; Moriggl, R (2015): Loss of IL-6/Stat3 signalling drives metastatic prostate cancer in mice and men. -Third Annual Meeting of the International Cytokine & Interferon Society ; OKT 11-14, 2015; Bamberg, GERMANY.

Pencik, J; Moriggl, R (2015): STAT3 regulated ARF expression suppresses prostate cancer metastasis. 2015 C.E. Alken-Stiftung; NOV 26-28, 2015; Rottach-Egern, Germany. 2015.

Pencik, J; Schlederer, M; Gruber, W; Unger, C; Walker, SM; Chalaris, A; Marie, I; Hassler, MR; Javaheri, T; Aksoy, O; Blayney, JK; Mazal, P; Grebien, F; Egger, G; Poli, V [and 19 others] (2015): Loss of IL-6/Stat3 signalling drives metastatic prostate cancer in mice and men. 3rd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Bamberg, GERMANY, Germany, OCT 11-14, 2015. Cytokine (76), 1 112-112.

Wingelhofer, B; Heyes, EC; Lewis, AM; Cumaraswamy, AA; Sadovnik, I; Valent, P; Kubicek, S; Gunning, PT; Moriggl, R (2015): Targeting STAT5 in Hematopoietic Malignancies. 3rd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Bamberg, GERMANY, Germany, OCT 11-14, 2015. Cytokine (76), 1 77-77.

Berger, A; Hoelbl-Kovacic, A; Menzl, I; Kubicek, S; Moriggl, R; Gouilleux, F; Sexl, V (2014): Characterization of STAT5 serine phosphorylation as a drug target in BCR-ABL+ leukemia. -24. Vetpharm Symposium; SEP 11-12,2014; Zuerich, SWITZERLAND.

Poster

Dey, S; Sorger, H; Vieyra-Garcia, P; Araujo, ED; Graf, R; Spiegl, B; Schlederer, M; Graier, T; Perchthaler, I; Fink-Puches, R; Cerroni, L; Surbek, M; Pirker, C; Berger, W; Orlova, A [and 8 others] (2021): STAT5 is a therapeutically targetable vulnerability in leukemic cutaneous T-cell lymphoma. 47th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF), Online, Germany, March 04‐06, 2021. Exp Dermatol (30), 3 E100-E101.

Schönefeldt, S; Suske, T; Wais, T; Aung, MMK; Kraupp, S; Zahma, S; Bekiaris, V; Moriggl, R; Neubauer, HA. (2021): A novel pre-clinical model for γδ T cell lymphoma driven by STAT5B N642H. The 9th International γδ T Cell Conference; NOV 5-8, 2021; Zhuhai, China. 2021.

Aksoy, O; Pencik, J; Varady, A; Moazzami, A; Schlederer, M; Balber, T; Susani, M; Hassler, M; Greiner, G; Javaheri, T; Turner, S; Egger, G; Moriggl, R; Culig, Z; Merkel, O; Kenner, L (2019): Cooperative Androgen and Thyroid Hormone Signaling Drives Prostate Cancer. 52nd Conference of the European-Society-of-Human-Genetics (ESHG), Gothenburg, Sweden, JUN 15-18, 2019. Eur J Hum Genet (27), S2 1595-1596.

Maurer, B; Pham, HTT; Prchal-Murphy, M; Nivarthi, H; Wingelhofer, B; Schlederer, M; Grausenburger, R; Winkler, S; Halbritter, F; Farlik, M; Bock, C; Kenner, L; Kolbe, T; Rülicke, T; Müller, M [and 2 others] (2017): Graded STAT5A or STAT5B activity promote T-cell neoplasia. STATs: Importance In Basic & Clinical Cancer Research; Nov 15-18, 2017; Cold Spring Harbor, United States (USA). 2017.

Kinslechner, K; Schörghofer, D; Schütz, B; Vallianou, M; Röhrl, C; Hengstschläger, M; Moriggl, R; Stangl, H; Mikula, M (2016): The HDL receptor controls the metabolic phenotype of human metastatic melanoma cells. 16th World Congress on Cancers of the Skin, Vienna, AUSTRIA, Austria, AUG 31 - SEP 3, 2016. Melanoma Res (26) E17-E17.

Wingelhofer, B; Heyes, EC; Maurer, B; Lewis, AM; Cumaraswamy, AA; Sadovnik, I; Berger-Becvar, A; Sexl, V; Valent, P; Kubicek, S; Gunning, PT; Moriggl, R (2016): Identification of a novel STAT5 inhibitor to interfere with the oncogenic activities of STAT5 in AML. 21st Congress of the European-Hematology-Association, Copenhagen, DENMARK, Denmark, JUN 09-12, 2016. Haematologica (101), S1 211-211.

Maurer, B; Nivarthi, H; Prchal-Murphy, M; Wingelhofer, B; Chen, D; Winkler, S; Prochazkova, J; Schlederer, M; Pham, H; Loizou, JI; Kenner, L; Sexl, V; Kolbe, T; Kralovics, R; Müller, M [and 2 others] (2015): An activating STAT5 mutation is sufficient for Peripheral T Cell Lymphoma formation. 3rd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Bamberg, GERMANY, Germany, OCT 11-14, 2015. Cytokine (76), 1 77-77.

Pencik, J; Moriggl, R (2015): Aberrant STAT3-ARF signaling targets distinct subgroups of lethal prostate cancer. -12th Charles Rodolphe Brupbacher Symposium Breakthroughs in Cancer Research and Therapy; JAN 28-30, 2015; Zurich, Switzerland.

© Veterinärmedizinische Universität Wien Hilfe und DownloadsErklärung zur Barrierefreiheit